Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AdvisorShares Psychedelics ETF (NY: PSIL )

12.01 -0.10 (-0.81%)
Official Closing Price Updated: 8:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,299
Open 12.15
Bid (Size) 11.75 (2)
Ask (Size) 16.00 (2)
Prev. Close 12.10
Today's Range 11.93 - 12.20
52wk Range 7.140 - 16.20
Shares Outstanding 7,499
Dividend Yield 0.91%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
5 ETFs That Beat Market Turmoil With Gains Last Week
Last week had Wall Street facing volatility, tech earnings disappointments, mixed labor data, and rising inflation fears. Gold hit record highs. 
Via Benzinga
Topics ETFs Economy
Exposures Interest Rates
High-Momentum ETFs Leading the Market This Year
Momentum investors looking to start 2025 off on good footing might look no further than these high-flying ETFs, each of which has returned 14% or more in 2025. 
Via MarketBeat
Topics ETFs

Performance

YTD
-0.95%
-0.95%
1 Month
-20.50%
-20.50%
3 Month
+9.71%
+9.71%
6 Month
+53.84%
+53.84%
1 Year
-21.54%
-21.54%

More News

Read More
Small-Cap NRx Pharma’s Stock Draws Heavy Retail Buzz After Securing $27M Funding
Via Stocktwits
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish
Via Stocktwits
5 Best-Performing Sector ETFs Of Q4
Via Talk Markets
Topics ETFs
Why Is Penny Stock Clearmind Gaining Today?
Via Benzinga
5 Best-Performing Sector ETFs Midway In Q4
Via Talk Markets
Topics ETFs
Top And Flop ETFs Of The First Half
Via Talk Markets
Topics ETFs
Best And Worst ETF Zones Of Q2
Via Talk Markets
Topics Artificial Intelligence ETFs Economy
Exposures Artificial Intelligence Interest Rates
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
Via Benzinga
Exposures Product Safety
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
Via Benzinga
Mental Health Mavericks: 3 Stocks Changing the Game
Via InvestorPlace
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
Via Benzinga
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
Via Benzinga
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
Via Benzinga
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
Via Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
Via Benzinga
Psychedelic Drug Stocks Index Up In December; Down YTD
Via Talk Markets
Psyched: Biden's Big Decision On Psychedelics Therapy; LSD Anxiety Results; Matthew Perry Autopsy And More
Via Benzinga
Psychedelic Drug Stocks Index Declined 1.6% This Week
Via Talk Markets
Topics ETFs
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
Via Benzinga
5 Largest Psychedelic Compound-Based Drug Stocks Up 3% Last Week
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.